Alderley Park, UK, 11 August 2021: BiVictriX Therapeutics plc, an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, is pleased to announce the admission of its entire issued and to be issued ordinary share capital (the “Ordinary Shares”) to trading on the AIM market of the London Stock Exchange (“Admission”).

The commencement of trading of the Company’s Ordinary Shares follows a successful oversubscribed placing by SP Angel Corporate Finance LLP (“SP Angel”), raising gross proceeds of £7.5 million at a price of 20 pence per Ordinary Share. At Admission, the market capitalisation of the Company will be approximately £13.2 million.

Dealings have commenced at 8.00 a.m. today under the ticker symbol “BVX” and the ISIN number GB00BNXH3K91.

Tiffany Thorn, Chief Executive Officer and Founder of BiVictriX Therapeutics plc, said: “Today’s listing on London’s AIM market is a major milestone for BiVictriX. Our vision is to revolutionise cancer therapy for the most difficult to treat cancers, making curative treatments available to all. The funds raised will help us to accelerate our growth and expedite the development and delivery of our pioneering, highly selective cancer therapeutics to patients diagnosed with some of the most challenging cancers and supporting patients who are currently in urgent need of more effective medicines.

“I would like to take this opportunity to offer our sincere gratitude and thanks to all of our staff, advisers and shareholders who have been instrumental in getting us to where we are today. I would also like to take this opportunity to welcome new shareholders to the register and thank them for their support in enabling us to continue to carry out this critical work. I look forward to life as a public company and progressing our development programmes to the next stage with the support of our shareholders.”

Read RNS HERE

Investor Relations Section